Wednesday, November 24, 2004

:Vioxx case: a failure to protect the public

Seattle Times - Seattle,WA,USA
The decision by Group Health Cooperative in Seattle not to give the drug Vioxx to its patients five years ago supports a whistleblower's assertion last week ...
See all stories on this topic

Where Do We Go After Vioxx?
CBS News - USA
(CBS) The recent recall of the arthritis drug Vioxx has a lot of patients worried ... Are drugs in the same family as Vioxx still available for arthritis pain? ...
See all stories on this topic

Glaxo Says 45 Drugs Are Now in Mid-Stage Testing (Update2)
Bloomberg - USA
... The company also showed early data on its Vioxx-class pain drug, 406381, suggesting the medicine was safe and effective, though could not say when it would ...
See all stories on this topic

Vioxx removal raises more questions
AM850 - Florida,USA
Nearly two months after the prescription arthritis drug Vioxx was pulled off the market because of heart attack risks, the controversy is still brewing. ...


Trying to Look Past Vioxx
RedNova.com - Dallas,TX,USA
Will the cardiac risks that last month forced Merck to yank its painkiller Vioxx affect other drugs in the widely used class of Cox- 2 inhibitors? ...


Post-Vioxx, aspirin appeals to Aspenites
Aspen Times - Aspen,CO,USA
... But with the recent recall of the hailed painkiller Vioxx, local pharmacies and health-care institutions have seen a reversion to what doctors are calling the ...


Experts urge better scrutiny of medicines
San Jose Mercury News (subscription) - San Jose,CA,USA
... proposed several times, usually after a spectacular drug imbroglio like the recent withdrawal of the popular arthritis drug and painkiller Vioxx because it was ...
See all stories on this topic

Arthritis Pills Little Use in Beating Pain -Study
Reuters - NY,USA
... But there are mounting concerns about their safety, following the withdrawal of Merck & Co Inc's COX-2 drug Vioxx in September due to heart attack risk. ...



FDA Vioxx Whistleblower

The New York Times > Business > Questions Are Seen on Merck's Stance on Pain Drug's Use